BMS, Lilly, Sanofi and Novartis top Big Pharma’s growth fortunes for next decade: Analysts

Tracy Staton

Predicting the future–particularly when it comes to Big Pharma's prospects for and earnings–is a favorite pastime among industry-watchers. Even better when the predictions come from who've dug deeply into company numbers and documents. Bernstein's Tim Anderson and his team did just that, and their conclusions are part of a new research report to investors. 

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS